|
Real-time Estimate
Tradegate
04:00:01 21/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 140.85 EUR | -12.35% |
|
0.00% | +1.81% |
| 10:32pm | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 09:59pm | Cancer vaccines finally garner the spotlight |  |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 255,775 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -11.13% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 275,101 | 267,427 | 258,922 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -11.6% | -2.79% | -3.18% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 21.1x | 18.4x | 16x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.75x | 4.21x | 3.58x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.2x | 1.1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.04x | 3.83x | 3.59x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.35x | 4x | 3.63x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.4x | 11x | 9.68x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 13.1x | 11.5x | 10.1x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 29.2x | 20.6x | 17.9x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.42% | 4.85% | 5.59% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.325 | 3.528 | 3.662 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.02% | 2.14% | 2.22% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.807 | 8.959 | 10.31 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.6% | 39.4% | 35.5% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,248 | 66,838 | 71,269 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,271 | 24,391 | 26,737 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,047 | 23,260 | 25,555 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,070 | 13,716 | 15,668 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,326 | 11,652 | 3,147 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 164.91 | 164.91 | 164.91 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 10/2/22 | 9/2/23 | 8/2/24 | 6/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 36.57x | 13.2x | 26.79x | 0.54% | 1,141B | |
| 30.41x | - | - | 1.96% | 659B | |
| 33.95x | 7.85x | 16.34x | 2.58% | 470B | |
| 20.47x | 4.85x | 12.03x | 2.72% | 366B | |
| 22.39x | 5.8x | 14.38x | 2.75% | 302B | |
| 21x | 4.33x | 12.29x | 2.03% | 254B | |
| 27.98x | 7.21x | 12.8x | 2.28% | 239B | |
| 13.62x | 4.84x | 10.15x | 3.77% | 207B | |
| -45.1x | 6.51x | 25.42x | 2.23% | 183B | |
| Average | 17.92x | 6.82x | 16.27x | 2.32% | 424.55B | |
| Weighted average by Cap. | 25.80x | 8.63x | 18.95x | 1.88% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- ZEG Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
